Skip to main content
COO logo

The Cooper Companies, Inc. (COO) Stock: Price, Forecast & Analyst Target

The Cooper Companies, Inc. (COO) — MoonshotScore 40/100 (Weak band), calculated Nov 18, 2026. Price $60.33 (-0.69%), as of the Nov 19, 2026 trading session; market cap $11.5B. Expected results Dec 3, 2026.

Listing-status flag — 8-K Item 3.01, filed Sep 12, 2023.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 74.34× (cash as of Jul 31, 2026) · expected results Dec 3, 2026

$60.33 −$0.42 (-0.69%) Market Cap $11.5B

The Cooper Companies, Inc. · COO · NASDAQ · Healthcare · Medical - Instruments & Supplies

Research dated 2026-09-13: Cooper combines contact lenses with women’s and fertility health products, with CooperVision contributing the larger share of revenue. The case hinges on whether lens growth can regain momentum while CooperSurgical expands and cash generation carries a debt load far above cash.

Price as of Nov 19, 2026

Key Statistics

40 of 100

MoonshotScore v2 · The Cooper Companies (COO)

Weak
Business Quality Elite (80)
Financial Safety Okay (55)
Valuation Fair (67)
Growth Durability Compounding (88)
Momentum Rising (60)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and elite growth. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Rising.

  • EPS beat 7 of the last 8 reports
  • expected results Dec 3, 2026
  • Altman Z 3.00 · Piotroski F 7

Helping: business quality, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for COO (57 recorded, newest six shown)
RecordedScoreBand
40Weak
40Weak
40Weak
40Weak
40Weak
40Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$60.33
Change on the day-0.69%
52-week range$51.01–$89.83
Market capitalisation$11.5B—
Price / earnings (trailing)20.72
Shares traded on the day2.10M
Beta (volatility vs the S&P 500)0.83

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $54, high $84, latest $60. 4 reported quarters marked, 4 above and 0 below the recorded estimate. 1 other dated event marked. $84 $54 high $84 Dec 4, 2025 · Earnings results · reported above the recorded estimate · close $811Mar 5, 2026 · Earnings results · reported above the recorded estimate · close $772Jun 4, 2026 · Earnings results · reported above the recorded estimate · close $673Sep 9, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $544Sep 9, 2026 · Earnings results · reported above the recorded estimate · close $545 Oct 17, 2025 Nov 19, 2026 · $60 $72Oct 17, 2025$70Oct 31, 2025$72Nov 14, 2025$78Nov 28, 2025$82Dec 12, 2025$83Dec 26, 2025$83Jan 9, 2026$81Jan 23, 2026$82Feb 6, 2026$84Feb 20, 2026$77Mar 6, 2026$70Mar 20, 2026$70Apr 2, 2026$70Apr 17, 2026$62May 1, 2026$60May 15, 2026$61May 29, 2026$68Jun 12, 2026$71Jun 26, 2026$71Jul 10, 2026$70Jul 24, 2026$74Aug 7, 2026$76Aug 21, 2026$70Sep 4, 2026$55Sep 18, 2026$57Oct 2, 2026$58Oct 16, 2026$60Oct 30, 2026$63Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • Looking ahead, we expect MiSight growth to be in the low teens in Q4 against a difficult prior year comparison, resulting in roughly 20% growth for this full year and setting the stage for a promising 2027, supported by continued momentum in existing markets and the upcoming launch of MyDay MiSight toric.

    Albert White · Statement from

  • For Q4, we expect consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0% to 2%. We expect CooperVision revenue of $692 million to $706 million, down 2% to flat organically.

    Brian Andrews · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for The Cooper Companies (COO): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Moderate
Growth Durability Strong
Momentum Moderate

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Moderate
Revenue Growth Neutral
Debt/Equity Neutral
ROE Neutral
Gross Margin Strong

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is The Cooper Companies (COO), and what does it report?

Short answer · as of

CooperVision sells spherical, toric, multifocal and specialty contact lenses for needs ranging from astigmatism and presbyopia to myopia and dry eyes.

CooperSurgical serves women’s and family health through clinical devices, fertility consumables and services, genetic testing, diagnostics and contraception.

Consolidated revenue therefore blends lens purchases across global markets with demand from fertility clinics and other healthcare providers. CooperVision supplies the larger revenue base, so contact-lens performance has greater influence on the reported top line even though CooperSurgical broadens the business beyond vision correction.

2 · Latest results

What do the latest results show for The Cooper Companies (COO)?

Revenue eased from the prior period, while operating profit and net income swung sharply positive after a loss. Revenue missed consensus even as the reported earnings measure exceeded expectations, so the profit rebound was materially stronger than the sales trend.

Management attributes near-term CooperVision weakness to channel inventory actions in the Americas and continued challenges in Asia Pacific, while describing Europe, the Middle East and Africa as resilient. Its outlook pairs muted vision performance with continued organic growth at CooperSurgical and sustained MiSight momentum despite a difficult comparison.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$1.07B Jul 31, 2026
Latest quarter · R&D
$41.60M Jul 31, 2026
Latest quarter · SG&A
$401.30M Jul 31, 2026
Latest quarter · FMP standardized operating result
$222.40M Jul 31, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Jul 31, 2026$1.07B$41.60M$401.30M$222.40M
Apr 30, 2026$1.08B$42.50M$676.20M−$31.00M
Jan 31, 2026$1.02B$44.30M$390.20M$212.80M
Oct 31, 2025$1.07B$41.40M$419.20M$140.40M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.07B Sep 9, 2026
Latest report · revenue estimate
$1.10B Sep 9, 2026
Latest report · revenue vs estimate
Below estimate Sep 9, 2026
Latest report · EPS vs estimate
Above estimate Sep 9, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Sep 9, 2026$1.07B$1.10B$1.1500$1.1200
Jun 4, 2026$1.08B$1.05B$1.2100$1.1000
Mar 5, 2026$1.02B$1.02B$1.1000$1.0300
Dec 4, 2025$1.07B$1.06B$1.1500$1.1100
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Jul 2025$1.06B$98M$0.49 (diluted)
Q4 FY2025$1.07B$85M$0.43 (diluted)
Q1 FY2026$1.02B$131M$0.66 (diluted)
Q2 FY2026$1.08B-$78M-$0.40 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for The Cooper Companies (COO)?

Short answer

Cash and short-term investments were $154.70M at the Jul 31, 2026 balance-sheet date. Operating cash flow was $341.70M for the quarter ended Jul 31, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Operating cash flow has remained positive throughout the displayed history, and the cash balance has risen across recent periods. Current assets cover current liabilities, but quick assets do not; cash also remains small beside total debt, while the trailing free-cash-flow yield is thin.

Annual revenue has advanced, but net income has moved unevenly even as research and development spending climbed. A prolonged CooperVision slowdown would matter disproportionately because that segment supplies most revenue, and weaker cash conversion would leave less flexibility against the debt burden.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$341.70M Jul 31, 2026
Previous quarter · operating cash flow
$182.80M Apr 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Jul 31, 2026$341.70M−$68.70M
Apr 30, 2026$182.80M−$86.40M
Jan 31, 2026$260.90M−$102.20M
Oct 31, 2025$247.90M−$98.00M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at The Cooper Companies (COO)?

Short answer · as of

The next earnings report is expected on Dec 3, 2026.

Americas lens sales are the immediate operational tell. Stabilization would support management’s view that channel inventory actions are a near-term drag, while continued weakness would make that explanation less reassuring; the contrast between resilient European markets and challenged Asia Pacific markets deserves the same scrutiny.

MiSight growth and the MyDay MiSight toric rollout will show whether CooperVision can create product momentum despite softer regional demand. At CooperSurgical, sustained organic growth would demonstrate that the smaller business can offset some vision weakness.

Compare revenue with consensus alongside earnings at the scheduled report. Recent releases have repeatedly exceeded earnings expectations, but revenue has not cleared expectations consistently, making top-line delivery the cleaner confirmation of renewed operating momentum.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. Within this, we expect regional performance trends to be broadly consistent with Q3, with the Americas reflecting the impact of channel inventory actions, EMEA delivering another solid quarter and Asia Pac continuing to face near-term challenges. We expect CooperSurgical revenue of $364 million to $374 million, representing organic growth of 4% to 6%.

    Brian Andrews ·

  2. Finally, while the strategic review process was extremely challenging for our teams, it provided valuable insights, and we believe we are well positioned to execute our plans and deliver strong performance in 2027 and beyond.

    Albert White ·

2 more statements are quoted under Upcoming events

5 · Peer comparison

How does The Cooper Companies compare with its peers?

Short answer

The Cooper Companies's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Relative to a business concentrated solely in contact lenses or fertility products, Cooper joins distinct demand engines under one company. Lens purchases depend on vision-correction demand, product mix and distributor ordering, while CooperSurgical participates in clinical procedures, fertility workflows, genetic testing and contraception.

Cooper is not simply a capital-equipment manufacturer: its offering spans lenses, consumables, devices and services. That breadth can produce different growth patterns within the same reporting period, although the larger CooperVision base keeps contact-lens execution more influential for consolidated results.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Neurocrine Biosciences, Inc. (NBIX) Named competitor$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
West Pharmaceutical Services, Inc. (WST) Same industry, near in market value$404.02 Nov 18, 2026$28.1B92 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Named competitor$29.83 Nov 19, 2026$12.5B84 5-pillar Nov 18, 2026
Haemonetics Corporation (HAE) Same industry, near in market value$120.37 Nov 19, 2026$5.48B83 5-pillar Nov 18, 2026
Merit Medical Systems, Inc. (MMSI) Same industry, near in market value$84.41 Nov 19, 2026$5.06B81 5-pillar Nov 18, 2026
Fresenius Medical Care AG & Co. KGaA (FMS) Named competitor$20.13 Nov 19, 2026$10.5B80 5-pillar Nov 18, 2026
AptarGroup, Inc. (ATR) Same industry, near in market value$140.34 Nov 19, 2026$8.90B77 5-pillar Nov 18, 2026
ICU Medical, Inc. (ICUI) Same industry, near in market value$175.76 Nov 19, 2026$4.40B73 5-pillar Nov 18, 2026
Repligen Corporation (RGEN) Same industry, near in market value$170.29 Nov 19, 2026$10.9B71 5-pillar Nov 18, 2026
Avantor, Inc. (AVTR) Same industry, near in market value$15.12 Nov 19, 2026$10.3B71 5-pillar Nov 18, 2026
Teleflex Incorporated (TFX) Same industry, near in market value$163.40 Nov 19, 2026$6.48B61 5-pillar Nov 18, 2026
Baxter International Inc. (BAX) Same industry, near in market value$25.39 Nov 19, 2026$13.1B57 5-pillar Nov 18, 2026
The Cooper Companies (COO) — this page$60.33$11.5B40

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$59.00 – $75.00
Consensus target
$65.11
Median target
$61.00

Consensus record · Captured .

Measured against a quoted price of $60.33 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 16, 2026

Transactions
6
Identified insiders
3
Purchases
5
Sales
0
Other transactions
1

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Reporting holders
658 Period end Sep 30, 2026
Previous quarter · holders
689 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.14,399,988
Vanguard Capital Management LLC12,807,874
State Street Corp8,860,902
Vanguard Portfolio Management LLC8,276,738
Browning West LP6,908,633

Tracked investors

Which of the 16 named investors we follow held COO in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported COO in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about The Cooper Companies (COO)?

Read these with our analysis →

The Cooper Companies Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

Why can CooperVision weaken even when patients still need contact lenses?

Management points to channel inventory actions in the Americas, so reported sales can reflect distributor ordering as well as patient demand. Regional performance also differs, with resilience in European markets alongside pressure in Asia Pacific.

How does CooperSurgical change the Cooper business mix?

CooperSurgical adds women’s health devices, fertility consumables and services, genetic testing, diagnostics and contraception to a company otherwise led by contact lenses. It is the smaller segment, but management expects it to grow while CooperVision faces near-term pressure.

What matters in the MyDay MiSight toric launch?

The rollout matters because it extends the MiSight franchise into toric lenses while management is seeking continued myopia-product momentum. Adoption would provide a product-specific counterweight to channel and regional pressure within CooperVision.

Why did Cooper’s latest profit rebound look stronger than its revenue trend?

Selling, general and administrative expense fell sharply from the prior period, coinciding with a return to operating profit even as revenue eased. The divergence makes expense discipline and the repeatability of the profit improvement important checks.

What is the COO stock price today?

The last price recorded for The Cooper Companies, Inc. (COO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the COO price target?

The analyst consensus price target for The Cooper Companies, Inc. (COO), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 78 figures on this page — 3 from SEC filings and earnings calls, 67 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Cash, investments and debt; Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • 1. What is The Cooper Companies (COO), and what does it report?: Business description; Revenue by segment; Sector / industry (provider taxonomy)
  • 2. What do the latest results show for The Cooper Companies (COO)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Revenue by segment
  • 3. What are the financial strengths and risks for The Cooper Companies (COO)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set; Annual revenue and net result (USD millions); Revenue by segment
  • 4. What should you watch next at The Cooper Companies (COO)?: Management outlook — dated call excerpts; Reported versus estimated, last 8 quarters; Next earnings report; Analyst revenue and earnings estimates (average); Revenue by segment
  • 5. How does The Cooper Companies compare with its peers?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Management outlook — dated call excerpts
  • FAQ: Why can CooperVision weaken even when patients still need contact lenses?: Management outlook — dated call excerpts; Business description
  • FAQ: How does CooperSurgical change the Cooper business mix?: Business description; Revenue by segment; Management outlook — dated call excerpts
  • FAQ: What matters in the MyDay MiSight toric launch?: Management outlook — dated call excerpts; Business description
  • FAQ: Why did Cooper’s latest profit rebound look stronger than its revenue trend?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.